Patent classifications
A61K31/196
USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES
The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with an isolated enveloped virus, having a membrane, to inactivate the membrane of the isolated enveloped virus. The subject is then treated with the enveloped virus having an inactivated membrane to vaccinate the subject against the enveloped virus. Further disclosed is an ex vivo vaccine composition including the compound of Formula (I) and an enveloped virus.
Hair removal admixture with wax, antiseptic, analgesic, moisturizing oil, and chemical depilatory: Hair removal chemical composite/creamy wax.
Hair removal Chemical composite/creamy wax. This waxing mixture is used to easily remove unwanted hair. To those seeking quick removal of hair without much pain, discomfort, sores, and the like. Helps to calm the skin during the hair removal procedure. Good for those seeking to do waxing by themselves, and doesn't need professional supervision. Quick hair removal waxing chemical composition, a waxing admixture for the 21st century. Less pain, more hair removal.
Hair removal admixture with wax, antiseptic, analgesic, moisturizing oil, and chemical depilatory: Hair removal chemical composite/creamy wax.
Hair removal Chemical composite/creamy wax. This waxing mixture is used to easily remove unwanted hair. To those seeking quick removal of hair without much pain, discomfort, sores, and the like. Helps to calm the skin during the hair removal procedure. Good for those seeking to do waxing by themselves, and doesn't need professional supervision. Quick hair removal waxing chemical composition, a waxing admixture for the 21st century. Less pain, more hair removal.
USE OF COLLAGEN COMPOSITIONS FOR INCREASING TELOMERE LENGTH
The present invention relates to use of a collagen composition for increasing telomere length in a cell, for treating or preventing conditions associated with reduced/shortened telomere length, and for dietary supplement and functional food uses for promoting healthy aging and longevity by mitigating telomere shortening.
USE OF COLLAGEN COMPOSITIONS FOR INCREASING TELOMERE LENGTH
The present invention relates to use of a collagen composition for increasing telomere length in a cell, for treating or preventing conditions associated with reduced/shortened telomere length, and for dietary supplement and functional food uses for promoting healthy aging and longevity by mitigating telomere shortening.
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Composition comprising porous silica particles carrying a cell fate modulating factor
A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.
Composition comprising porous silica particles carrying a cell fate modulating factor
A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.
Benzocarbonyl compounds
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.